Adaptyx Raises $14M in Seed Financing to Launch Wearable Platform for Continuous Multi-Analyte Molecular Monitoring

Adaptyx Biosciences announced today it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures.

Adaptyx’s biowearable platform redefines continuous health monitoring, moving beyond glucose to capture a much wider range of human biochemistry – including small molecules, electrolytes, hormones, drugs, and proteins – making visible what has long been hidden between lab visits. By pairing continuous molecular sensing with AI-powered analytics, the platform transforms these data streams into actionable insights, enabling earlier detection of health trends and timely interventions before issues escalate.

According to Vijit Sabnis, Ph.D., CEO & Co‑Founder, Adaptyx. “Lab tests are only snapshots of health and don’t capture the body’s changing physiology, leaving blind spots that prevent addressing many of today’s health challenges. Adaptyx gives patients and clinicians a continuous view of what’s happening inside the body, transforming previously unseen molecular signals into empowering insights. Our mission is to expand continuous monitoring beyond glucose to include the many molecules that drive human health, creating a rich data pipeline that guides patients and clinicians to make the best decisions at the right time. We're starting with life-saving clinical applications and will ultimately bring this capability to everyone.”

Adaptyx’s Molecular Switch Foundry accelerates biosensor development by integrating automated molecular design, parallelized screening, and AI‑driven optimization to compress development timelines from years to weeks. Proceeds from the financing will accelerate R&D and product development, expand the molecular switch pipeline, and support on-going clinical trials towards the company’s first application. Adaptyx will also scale its team across engineering, data science, and clinical operations.

Applications in development include:

• Heart Failure Management: Continuous monitoring of electrolytes, kidney function markers, and cardiac biomarkers enables safe medication titration, early detection of abnormalities, and prompt intervention before decompensation occurs.
• Hormone Optimization: Continuous hormone and metabolite profiling reveals rhythms and imbalances, supporting precise management of endocrine health, from metabolic disorders to fertility care.
• Care Delivery Augmentation: Real-time monitoring of drug levels and critical care biomarkers ensures optimal dosing, rapid clinical response, and reduced risk of complications.
• Personalized Wellness: Continuous tracking of molecular health markers provides visibility into stress, metabolism, and recovery, enabling proactive lifestyle adjustments and healthier aging.